101626-66-8

101626-66-8 structure
101626-66-8 structure
  • Name: Dobutamine tartrate
  • Chemical Name: Dobutamine tartrate
  • CAS Number: 101626-66-8
  • Molecular Formula: C22H29NO9
  • Molecular Weight: 451.47
  • Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
  • Create Date: 2022-09-12 19:08:47
  • Modify Date: 2024-01-08 19:10:49
  • Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion[1][2][3][4].

Name Dobutamine tartrate
Description Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion[1][2][3][4].
Related Catalog
In Vivo Dobutamine tartrate has a rapid onset of action and a short half-life [2]. Dobutamine tartrate (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice[3]. Dobutamine tartrate results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice[3]. Low doses of Dobutamine tartrate significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice[3]. Dobutamine tartrate increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost[3]. Dobutamine tartrate increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation[4]. Animal Model: Tgαq*44 mice (heart failure models)[3] Dosage: 0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose Administration: Intraperitoneal injection Result: Induced different response in cardiac function on a low and high dose in mice with with heart failure.
References

[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96.

[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402.

[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77.

[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44.

Molecular Formula C22H29NO9
Molecular Weight 451.47